Synthetic peptide, incretin-receptor agonist

Retatrutide

Also catalogued as LY3437943, LY-3437943.

CAS number: 2381089-83-2
Molecular formula: C221H342N46O68
Molecular weight: 4731.42 g/mol
PubChem CID: —

Identity

CAS number: 2381089-83-2
Molecular formula: C221H342N46O68
Molecular weight: 4731.42 g/mol
Residues: 39

An engineered 39-residue sequence with non-natural residues and a C20 fatty-diacid attachment at position 17; a plain one-letter rendering would misstate it.

What it is

Retatrutide (developed under the code LY3437943) is a synthetic peptide of thirty-nine residues engineered from the sequence of glucose-dependent insulinotropic polypeptide (GIP). The design incorporates non-natural amino-acid substitutions and a C20 fatty-diacid moiety attached through a linker at the lysine in position 17.

In the primary literature it is characterised pharmacologically as an agonist of the glucagon, GIP, and GLP-1 receptors. Its first-in-human characterisation, a phase 1b study, was published in 2022.

Regulatory status

Retatrutide is an investigational compound. It is not an approved drug in any jurisdiction.

Primary literature

Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet 2022;400(10366):1869–1881.
PMID 36354040

Citation titles are reproduced verbatim from the journal record. A citation documents the molecule's published identity and history; it is not a claim about the material sold here.

Loading…

What it is

In the primary literature it is characterised pharmacologically as an agonist of the glucagon, GIP, and GLP-1 receptors. Its first-in-human characterisation, a phase 1b study, was published in 2022.